MiMedx Group (NASDAQ:MDXG) Earns Market Outperform Rating from Analysts at Citizens Jmp

Citizens Jmp began coverage on shares of MiMedx Group (NASDAQ:MDXG) in a research report sent to investors on Monday, MarketBeat.com reports. The brokerage issued a market outperform rating and a $10.00 target price on the stock.

Several other research analysts have also recently issued reports on MDXG. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Mizuho dropped their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. UBS Group set a $10.00 target price on MiMedx Group in a research report on Monday. Finally, Citigroup started coverage on MiMedx Group in a research report on Monday. They issued a “market outperform” rating for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Trading Down 1.3%

NASDAQ:MDXG opened at $5.28 on Monday. MiMedx Group has a 1 year low of $4.89 and a 1 year high of $8.46. The stock has a market cap of $781.97 million, a P/E ratio of 19.56 and a beta of 1.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The stock has a 50-day simple moving average of $5.78 and a 200-day simple moving average of $6.60.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.05. The business had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%. As a group, analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds have recently modified their holdings of MDXG. CWM LLC raised its position in MiMedx Group by 63.8% during the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after buying an additional 1,892 shares during the last quarter. Legato Capital Management LLC increased its stake in shares of MiMedx Group by 18.5% during the third quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock worth $121,000 after acquiring an additional 2,708 shares during the period. HighMark Wealth Management LLC raised its holdings in MiMedx Group by 5.4% during the third quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock worth $390,000 after purchasing an additional 2,878 shares in the last quarter. SkyView Investment Advisors LLC lifted its position in MiMedx Group by 3.6% in the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock valued at $523,000 after purchasing an additional 3,032 shares during the period. Finally, Rafferty Asset Management LLC boosted its holdings in MiMedx Group by 4.6% in the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after purchasing an additional 3,064 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting MiMedx Group

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Q4 beat — MiMedx posted EPS of $0.14 vs. the $0.09 consensus and reported revenue of ~$118.1M, well above estimates; margins and ROE remained healthy, supporting the operational story. MiMedx Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Record results & buyback — The company announced record Q4 and FY2025 operating results and authorized a $100M share repurchase program, which can support the stock over time. MIMEDX Announces Record Fourth Quarter and Full-Year 2025 Results
• Neutral Sentiment: Full disclosure & commentary — Management hosted an earnings call (transcripts available) providing color on surgical growth initiatives and how the company plans to manage reimbursement shifts; useful for modeling but not an immediate price driver. MiMedx Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst coverage update — Citizens JMP began coverage, which may influence liquidity and analyst attention but has mixed near-term impact. Citizens JMP Begins Coverage on MiMedx
• Negative Sentiment: Below-Cons. FY2026 revenue guide — Management guided revenue of $340M–$360M for 2026, below the consensus (~$375M), citing reimbursement changes and a shift toward surgical growth that may take time to scale; that guidance shortfall is the primary negative catalyst. MiMedx targets $340M–$360M 2026 revenue while navigating reimbursement changes
• Negative Sentiment: Reimbursement risk — Management highlighted evolving reimbursement dynamics that could pressure near-term top-line growth and create execution risk as sales mix shifts toward surgical channels. MiMedx Q4 2025 Earnings Call Transcript (seekingalpha)

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.